What Prondil does

Prondil S.A. is a Uruguayan biotechnology company founded in the early 1990s by former executives of Cooper Animal Health (formerly Wellcome Research Laboratories), specializing exclusively in the development and production of veterinary vaccines and antigens for animal health. The company manufactures biological products — primarily clostridial bacterins/toxoids, Pasteurella and Mannheimia vaccines, anthrax vaccines, and botulism vaccines — for cattle, sheep, goats, pigs, horses, and camels. Its pipeline includes recombinant vaccine technology targeting infectious pancreatic necrosis in salmon (Project PIEP) and viral antigen development for bovine vaccines (Project Alianza) conducted jointly with Universidad de la República's Faculty of Sciences.

The product portfolio comprises roughly 18 branded SKUs organized under the PRONDICLOS (polyclostridial), PRONDIVAX (specialty clostridial combinations), PRONDIBOT, PRONDIPAST, PRONDISTAR, PRONDITHRAX, and PRONDIVAC lines. Production takes place at a single biosecure manufacturing facility in Montevideo under US CFR, European Pharmacopeia (PhEur), OIE, WHO, and Mercosur GMP standards, which supports export-grade quality credentials.

Prondil generates revenue through one-time product sales of veterinary vaccines and antigens, distributing both directly via its international sales force and indirectly through strategic alliances with major multinational veterinary companies that re-sell the same products under partner commercial names. End customers include livestock producers, veterinarians, and livestock technicians across more than 20 countries. Since December 2017, Prondil has operated as a wholly-owned subsidiary of MSD Animal Health (a Merck & Co. subsidiary), which provides global distribution leverage but also concentrates strategic decision-making with the parent. Public pricing is not disclosed; commercial inquiries route through a Merck email address, consistent with the integrated post-acquisition sales posture.

Name

Prondil

Legal name

Prondil S.A.

Website

https://prondil.com

Company type

Private

Founded year

1990

Operating status

Operating

Headcount range

51–100 employees

Short description

Prondil S.A. is a Uruguayan biotech manufacturer of veterinary vaccines and antigens — primarily clostridial, pasteurella, anthrax, and botulism vaccines for livestock — exporting to over 20 countries as a wholly-owned subsidiary of MSD Animal Health since 2017.

Ownership category

akta.pro rank

Product category

Veterinary Vaccines

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Livestock Vaccines (Cattle, Swine, Sheep & Goats) (HLAMAKAB)

akta.pro secondary industries

Veterinary Vaccines (Biologics) (HLAMAEAL), Vaccine R&D, Clinical/Field Trials & Regulatory Affairs (HLAMAKAM), Veterinary Pharmacy, Vaccine & Biologics Services (AFAEANAK)

Keywords

• Veterinary vaccines
• Animal health biotechnology
• Veterinary biologicals
• Livestock immunization
• Recombinant vaccine technology

Headquarters

HQ city

Montevideo

HQ country

Uruguay

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Veterinary vaccines and antigens: Prondil manufactures and exports veterinary biological products (vaccines and antigens) for animal health. Products are sold in over 20 countries both under the Prondil brand and under other commercial names, working in co-operation with major multinational veterinary companies.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Prondil is a biotechnology company that develops and manufactures veterinary vaccines and antigens for animal health, with 100% of its technical efforts focused on biological products. Its portfolio covers clostridial diseases (Blackleg, Enterotoxaemia, Tetanus, Botulism, Malignant Oedema, Pulpy Kidney), pasteurellosis, and anthrax across cattle, sheep, goats, pigs, horses, and camels. The company also pursues recombinant vaccine technology, including a project (PIEP) targeting infectious pancreatic necrosis in salmon.

Product overview

Prondil is a biotechnology company specializing in the development and production of high-quality veterinary vaccines and antigens for animal health. The product portfolio consists of multiple branded vaccine families targeting clostridial diseases, pasteurellosis, anthrax, and botulism across cattle, sheep, goats, horses, pigs, and camels. The core products include the PRONDICLOS line (polyclostridial vaccines in various formulations including PRONDICLOS, PRONDICLOS 10, PRONDICLOS B, PRONDICLOS P, PRONDICLOS P MAX, and PRONDICLOS PLUS), the PRONDIVAX line (specialized vaccines including BLACKQUARTER, BLACKQUARTER + ANTHRAX, BLACKQUARTER + BOTULISM, BOTULISM + ANTHRAX, MULTICLOSTRIDIAL 8, and PULPY KIDNEY variants), standalone vaccines (PRONDIBOT, PRONDITHRAX, PRONDIPAST, PRONDISTAR, PRONDIVAC TRIPLE BACTERINA), and antigen products. Products are available under Prondil's own brand and through partnerships with major multinational veterinary companies, distributed across over 20 countries worldwide.

Differentiator

Problem solved

Functional benefit

Brands

• PRONDIBOT: Vaccine for active immunization against Botulism for cattle, sheep, horses and goats
• PRONDICLOS
• PRONDICLOS 10
• PRONDICLOS B
• PRONDICLOS P
• PRONDICLOS P MAX
• PRONDICLOS PLUS
• PRONDIPAST
• PRONDISTAR
• PRONDITHRAX
• PRONDIVAC TRIPLE BACTERINA
• PRONDIVAX BLACKQUARTER
• PRONDIVAX BLACKQUARTER + ANTHRAX
• PRONDIVAX BLACKQUARTER + BOTULISM
• PRONDIVAX BOTULISM + ANTHRAX
• PRONDIVAX MULTICLOSTRIDIAL 8
• PRONDIVAX PULPY KIDNEY
• PRONDIVAX PULPY KIDNEY 1 SHOT

Products and services

• PRONDIBOT

Quantifiable outcome

• Vaccines have proven highly effective in each of the markets in which Prondil participates, with field results supporting product quality.

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Faculty of Sciences (Universidad de la República, Uruguay)coreStrategic or Co-development PartnerProndil maintains a constant relationship with the academic sector. The company has formed alliances with the Faculty of Sciences for joint R&D projects, including Project Alianza for the development of viral antigens for vaccine production, in collaboration with the Virology Section of the Faculty of Sciences.
• Faculty of Medicine (Universidad de la República, Uruguay)minorStrategic or Co-development PartnerJoint R&D projects and development activities carried out with research groups from the Faculty of Medicine for new products and improvement of existing processes.
• Faculty of Chemistry (Universidad de la República, Uruguay)minorStrategic or Co-development PartnerCollaborative R&D projects with research groups from the Faculty of Chemistry for product development and process improvement in biological production.
• Faculty of Veterinary Science (Universidad de la República, Uruguay)minorStrategic or Co-development PartnerJoint development projects for new products and improvement of existing processes carried out with research groups from the Faculty of Veterinary Science.
• ORT University (Universidad ORT, Uruguay)minorStrategic or Co-development PartnerCollaborative R&D projects carried out with research groups from ORT University as part of Prondil's strategy to strengthen research and development through academic sector alliances.
• INTA (Instituto Nacional de Tecnología Agropecuaria, Argentina)coreStrategic or Co-development PartnerIn August 2016, Prondil hosted a training course at its facilities on viral vaccine control techniques for bovine viral vaccines. The course was conducted by Dr. Viviana Parreño and Dr. Marina Bok of INTA Argentina, who are sector references and designers of various technical guides approved under CAMEVET. The 3-day training covered different methodologies to evaluate the potency of bovine viral vaccines for Development and Quality Control staff.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Virbac: Independent global animal health company specializing in vaccines and pharmaceuticals for livestock and companion animals, with a meaningful clostridial and bacterial vaccine portfolio. Closely comparable mid-sized competitor in livestock biologicals.
• Phibro Animal Health: Global animal health and nutrition company with a livestock vaccine portfolio and significant presence in emerging markets. Comparable as a peer in livestock biologicals, particularly in regions Prondil exports to.
• Vetoquinol: Independent French animal health company with livestock and companion animal pharmaceutical and biological product portfolios. Comparable as a mid-sized peer focused on veterinary medicines including vaccines for cattle and small ruminants.
• Biogénesis Bagó: Latin American veterinary biologics company specializing in livestock vaccines, including foot-and-mouth disease and clostridial products, with strong regional distribution. Highly comparable regional peer competing in the same geographies and species categories as Prondil.
• Ceva Santé Animale: Global animal health company headquartered in France with strong livestock vaccine franchises, particularly in poultry and ruminants. Comparable as a privately-held, internationally focused veterinary biologics manufacturer competing in similar clostridial and bacterial disease segments.

Regional players

• Biovac (South Africa): South African veterinary and human vaccine manufacturer with livestock vaccine exports across Africa. Comparable as an emerging-market veterinary biologics producer serving similar export-driven, price-sensitive livestock markets.

Broad incumbents

• Zoetis: Global leader in animal health and medicines, including a broad livestock vaccine portfolio (clostridial, respiratory, reproductive). Directly comparable as a livestock vaccine manufacturer serving cattle, sheep, goats, and pigs across global markets.
• Elanco Animal Health: Major global animal health company with livestock vaccine, parasiticides, and therapeutic offerings. Comparable as a peer in the broader veterinary biologics and pharmaceuticals space, including clostridial and respiratory vaccines for cattle and small ruminants.
• Boehringer Ingelheim Animal Health: Top-three global animal health company with extensive livestock and poultry vaccine portfolios and significant recombinant vaccine capabilities. Comparable as a competing multinational veterinary biologics manufacturer with global distribution.

Emerging players

• Indian Immunologicals Limited: Subsidiary of the National Dairy Development Board of India producing veterinary vaccines and human biologicals, with growing international export presence. Comparable as an emerging regional biologics manufacturer exporting to multiple geographies.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/laboratorio-prondil

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Prondil